How were GlobeImmune's earnings last quarter?

GlobeImmune, Inc. (OTCMKTS:GBIM) issued its quarterly earnings results on Thursday, May, 12th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.12. The biopharmaceutical company had revenue of $0.94 million for the quarter.

What other stocks do shareholders of GlobeImmune own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GlobeImmune investors own include OHR Pharmaceutical (OHRP) , Novavax (NVAX) , Premier Gold Mines (PG) , Algonquin Power & Utilities (AQN) , Nordic American Tankers (NAT) , (BAA) (BAA) , Petróleo Brasileiro S.A. - Petrobras (PBR) , Pengrowth Energy (PGH) , Absolute Software Co. (ABT.TO) (ABT) and Alacer Gold (ASR) .

How do I buy shares of GlobeImmune?

Shares of GBIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:GBIM

GlobeImmune (GBIM) Stock Price, News & Analysis

→ Elon Musk’s ChatGPT Could Soon Mint New Millionaires (From InvestorPlace) (Ad)

Free GBIM Stock Alerts

Compare

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: N/A
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Financials Short Interest

Get GlobeImmune alerts:

Ad InvestorPlace

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

And you could go along for the ride if you make this one simple move.

About GlobeImmune Stock (OTCMKTS:GBIM)

GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado. GlobeImmune, Inc. operates as a subsidiary of ImmunityBio, Inc.

Ad InvestorPlace

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

And you could go along for the ride if you make this one simple move.

GBIM Stock News Headlines

July 18, 2023 | investing.com

Bubang Co Ltd (014470)

July 18, 2023 | investing.com

Nihon Knowledge Co Ltd (5252)

April 16, 2024 | InvestorPlace (Ad)

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

April 21, 2023 | nasdaq.com

Nuvista Energy Breaks Below 200-Day Moving Average - Notable for NVA

January 9, 2023 | sg.finance.yahoo.com

GlobeImmune, Inc. (GBIM) stock historical prices & data – Yahoo Finance

September 15, 2022 | reuters.com

GBIM.PK - GlobeImmune Inc | Stock Price & Latest News | Reuters

See More Headlines

Receive GBIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GlobeImmune and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/12/2016
Today: 4/15/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: OTCMKTS:GBIM
Previous Symbol: NASDAQ:GBIM
CUSIP: N/A
CIK: 1245104
Web: www.globeimmune.com
Phone: (720) 667-2300
Fax: 303-625-2710
Employees: 2
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: -194.15

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Mr. C. Jeffrey Dekker CPA (Age 59)
President, Vice President of Finance, Treasurer & Secretary
Comp: $200.05k
Dr. Richard C. Duke
Scientific Founder & Member of Scientific Advisory Board
Dr. Donald Bellgrau
Scientific Founder & Chairman of The Scientific Advisory Board

Key Competitors

View All Competitors

GBIM Stock Analysis - Frequently Asked Questions

How were GlobeImmune's earnings last quarter?: GlobeImmune, Inc. (OTCMKTS:GBIM) issued its quarterly earnings results on Thursday, May, 12th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.12. The biopharmaceutical company had revenue of $0.94 million for the quarter.
What other stocks do shareholders of GlobeImmune own?: Based on aggregate information from My MarketBeat watchlists, some companies that other GlobeImmune investors own include OHR Pharmaceutical (OHRP), Novavax (NVAX), Premier Gold Mines (PG), Algonquin Power & Utilities (AQN), Nordic American Tankers (NAT), (BAA) (BAA), Petróleo Brasileiro S.A. - Petrobras (PBR), Pengrowth Energy (PGH), Absolute Software Co. (ABT.TO) (ABT) and Alacer Gold (ASR).
How do I buy shares of GlobeImmune?: Shares of GBIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:GBIM) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial